Premium
The glycoconjugate derived from a Leishmania major receptor for macrophages is a suppressogenic, disease‐promoting antigen in murine cutaneous leishmaniasis
Author(s) -
MITCHELL G.F.,
HANDMAN E.
Publication year - 1986
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/j.1365-3024.1986.tb01037.x
Subject(s) - glycoconjugate , cutaneous leishmaniasis , immunology , glycolipid , leishmania , leishmaniasis , leishmania major , biology , antigen , population , parasite hosting , medicine , bioinformatics , environmental health , world wide web , computer science
Summary Lymphoid cells from genetically‐susceptible BALB/c mice immunized against a glycoconjugate of the protozoan parasite, Leishmania major , promote chronic cutaneous disease in BALB/c nude mice. This cell population therefore differs from cells harvested from non‐immunized BALB/c mice that are known to be potent mediators of protection against cutaneous leishmaniasis in minimally‐reconstituted, syngeneic nude mice. The glycoconjugate when injected into genetically‐resistant C57BL/6 mice will increase the size and persistence of cutaneous lesions. Recent studies have established that the water soluble glycoconjugate is derived from a membrane‐bound glycolipid that is a receptor used by the parasite in the attachment to macrophages. This glycolipid can protectively immunize mice against cutaneous leishmaniasis. Identification of a vaccinating glycolipid antigen and a suppressogenic component derived from it will greatly facilitate analysis of disease‐promoting and resistance‐promoting immunity in cutaneous leishmaniasis. However, the fact that a host‐protective antigen contains a disease‐promoting component may militate against the immediate use of this molecular vaccine in man.